Press Releases
-
Stan Lapidus Joins Calviri's Scientific Advisory Board
October 30th, 2023
-
Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients
May 23rd, 2023
-
Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial
June 7th, 2022
-
Calviri, Inc. Announces Formation of Scientific Advisory Board
May 13th, 2022
-
Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation
October 4th, 2021
-
Calviri Appoints Marc Wolff Chief Executive Officer
April 12th, 2021
-
Calviri Named Most Fundable Company by Pepperdine Graziadio Business School
December 1st, 2020
-
Calviri Appoints Michael McCallister to Board of Directors
November 23rd, 2020
-
Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilities
October 13th, 2020
-
Calviri Appoints Michael Chambers to Board of Directors
August 18th, 2020
-
Cancer Vaccine Start Up, Calviri, Closes Successful Seed Funding
April 2nd, 2020
-
Calviri Awarded NCI Grant for the Development of a New Blood Test That May Predict Responders to Checkpoint Inhibitor Therapies
October 24th, 2019
-
Caliviri Demonstrates That RNA Processing Errors Are a Rich Source of Tumor Neoantigens for Cancer Vaccines
October 3rd, 2019